Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Prime Medicine (PRME) Tax Provisions (2021 - 2024)

Prime Medicine (PRME) has disclosed Tax Provisions for 4 consecutive years, with -$134000.0 as the latest value for Q2 2024.

  • For the quarter ending Q2 2024, Tax Provisions fell 532.26% year-over-year to -$134000.0, compared with a TTM value of -$134000.0 through Mar 2025, down 335.09%, and an annual FY2023 reading of -$279000.0, up 70.57% over the prior year.
  • Tax Provisions was -$134000.0 for Q2 2024 at Prime Medicine, down from $134000.0 in the prior quarter.
  • Across five years, Tax Provisions topped out at $1.4 million in Q4 2021 and bottomed at -$532000.0 in Q1 2022.
  • Average Tax Provisions over 4 years is $14000.0, with a median of -$121000.0 recorded in 2023.
  • Peak annual rise in Tax Provisions hit 166.34% in 2024, while the deepest fall reached 532.26% in 2024.
  • Year by year, Tax Provisions stood at $1.4 million in 2021, then plummeted by 113.61% to -$186000.0 in 2022, then soared by 41.94% to -$108000.0 in 2023, then dropped by 24.07% to -$134000.0 in 2024.
  • Business Quant data shows Tax Provisions for PRME at -$134000.0 in Q2 2024, $134000.0 in Q1 2024, and -$108000.0 in Q3 2023.